Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancerAleix Prat, Ana Vivancos, Fara Brasó‐Maristany et al.|Nature Communications|2023Cited by 65
Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early responseFara Brasó‐Maristany, Mafalda Oliveira, Claudette Falato et al.|Nature Communications|2024Cited by 23
Abstract PD13-01: PD13-01 Elacestrant in postmenopausal women with estrogen receptor positive and HER2-negative early breast cancer: primary efficacy and safety analysis of the preoperative, window of opportunity SOLTI-1905-ELIPSE trialMaría Vidal, Meritxell Bellet Ezquerra, Tomás Pascual et al.|Cancer Research|2023Cited by 12
124O Patritumab deruxtecan (HER3-DXd) in hormonal receptor-positive/HER2-negative (HR+/HER2-) and triple-negative breast cancer (TNBC): Results of part B of SOLTI TOT-HER3 window of opportunity trialMafalda Oliveira, Aleix Prat, Tomás Pascual et al.|ESMO Open|2023Cited by 8
Elacestrant in Women with Estrogen Receptor–Positive and HER2-Negative Early Breast Cancer: Results from the Preoperative Window-of-Opportunity ELIPSE TrialMaría Vidal, Meritxell Bellet, Claudette Falato et al.|Clinical Cancer Research|2025Cited by 7